Contract to Maintain MSI-DS 30mm Weapon System

MS International PLC
01 September 2023
 

1 September 2023

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act 2018


MS INTERNATIONAL plc

(the "Company")

 

CONTRACT TO MAINTAIN THE MSI-DS 30mm WEAPON SYSTEM FOR THE US NAVY

 

The Company is pleased to announce that a maintenance contract has been awarded by the United States Navy ('NAVSEA') to our wholly owned subsidiary company, MSI-Defence Systems US LLC, which is based in Rock Hill, South Carolina, USA.

 

The contract is on a sole source basis for the procurement of supplies and services to maintain the US Navy Mk38 MOD4 weapon system (which is the US Navy nomenclature for our MSI-DS 30mm naval weapon system). The contract commences with immediate effect, with a budget ceiling of $49.8 million over the period to 30th June 2028.

 

In the Company's annual financial report for the year ended 30 April 2023, the Chairman, Michael Bell, stated "Regarding the ongoing opportunities in the US, we cautiously believe that we are well placed to be awarded a contract to supply our MSI-DS 30mm naval weapon system to the US Navy."

 

The Company has yet to be awarded a production and supply contract related to the US Navy Mk38 MOD4 weapon system but the awarding of this maintenance supply and service contract substantially increases our confidence that we shall also be awarded such a production contract from "NAVSEA", shortly.

 

 

For further information please contact:

 

MS INTERNATIONAL plc                         Tel: +44 (0)13 0232 2133

Michael Bell

 

Shore Capital

Nomad and Broker                                       Tel: +44 (0)20 7408 4090

Patrick Castle/Daniel Bush/Lucy Bowden

 

                       

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings